- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Glenmark Pharmaceuticals Ltd up for third straight session | 2 | capitalmarket.com | ||
| 26.06. | 10 Stocks To Buy For Short Term: Analysts suggest buying largecap, midcap scrips for 2 weeks; Glenmark Pharma, LIC, HPCL on the list | 2 | ZEE Business | ||
| 24.06. | Glenmark Pharma launches TEVIMBRA in India | 3 | capitalmarket.com | ||
| 18.06. | Glenmark pharma's US facility receives five observations after USFDA GMP inspection | 4 | capitalmarket.com | ||
| 17.06. | ACUCORT AB: AcuCort signs Letter of Intent (LOI) with Glenmark Pharmaceuticals for Germany and five additional European countries | 2 | Cision News | ||
| 13.06. | Glenmark's technical breakout signals rally ahead: Religare's Ajit Mishra | 4 | Times of India | ||
| 09.06. | Glenmark Pharma rises after zanubrutinib launch in India | 3 | capitalmarket.com | ||
| GLENMARK PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 02.06. | Ichnos Glenmark Innovation: Full Dose-Escalation Data Show Continued High Response Rates and Favorable Safety Profile of ISB 2001, a First-in-Class BCMA × CD38 × CD3 Trispecific Antibody, for the Treatment of Relapsed/Refractory Multiple Myeloma | 288 | PR Newswire | TRIgnite-1 study shows an overall response rate (ORR) of 74% across nine dose levels, in heavily pretreated patients with a median of six prior lines of therapy
ORR is remarkably high... ► Artikel lesen | |
| 06.05. | Ichnos Glenmark Innovation (IGI) erhält FDA-Fast-Track-Zulassung für ISB 2001 zur Behandlung des rezidivierten/refraktären multiplen Myeloms | 317 | news aktuell | New York (ots/PRNewswire) - Ergebnisse des Dosis-Eskalationsteils der klinischen Phase-1-Studie mit ISB 2001 bei Patienten mit stark vorbehandeltem multiplem Myelom werden auf der ASCO-Jahrestagung... ► Artikel lesen | |
| 05.05. | Ichnos Glenmark Innovation (IGI) Receives U.S. FDA Fast Track Designation for ISB 2001 for Relapsed/Refractory Multiple Myeloma | 281 | PR Newswire | Results from the dose-escalation portion of the Phase 1 clinical study of ISB 2001 in patients with heavily pretreated multiple myeloma to be presented at the 2025 ASCO Annual Meeting
NEW... ► Artikel lesen | |
| 17.04. | Glenmark Pharma's US arm set to launch generic Adderall tablets | 3 | capitalmarket.com | ||
| 16.04. | Glenmark To Launch Generic Adderall Tablets In May 2025 | 446 | AFX News | WASHINGTON (dpa-AFX) - Glenmark Pharmaceuticals Inc., USA, a wholly owned subsidiary of Glenmark Pharmaceuticals Limited (GLENMARK.NS) Wednesday announced its upcoming May 2025 launch of a generic... ► Artikel lesen | |
| 13.04. | Glenmark, Sun Pharma, Zydus Recall Medicines In US Over Manufacturing Issues | 3 | The Free Press Journal | ||
| 11.04. | Glenmark Pharmaceuticals Ltd slips for fifth straight session | 3 | capitalmarket.com | ||
| 01.04. | Glenmark Launches Vancomycin Hydrochloride For Injection In 3 Doses | 321 | AFX News | NEW DELHI (dpa-AFX) - Glenmark Pharmaceuticals Inc., USA, affiliated to India-based Glenmark Pharmaceuticals Ltd., announced Tuesday the launch of Vancomycin Hydrochloride for Injection USP... ► Artikel lesen | |
| 01.04. | Glenmark launches Vancomycin Hydrochloride for injection USP in the USA | 4 | capitalmarket.com | ||
| 25.03. | Glenmark Pharmaceuticals Ltd: Glenmark Pharmaceuticals Launches Pioneering Nutrition Program to Fight Malnutrition in the Philippines | 331 | PR Newswire | MANILA, Philippines, March 25, 2025 /PRNewswire/ -- Glenmark Pharmaceuticals Ltd. (Glenmark), a leading research-led, global pharmaceuticals company has partnered with, Health Futures Foundation... ► Artikel lesen | |
| 21.03. | Glenmark Pharma gains as arm gets USFDA nod for Olopatadine Ophthalmic solution | 3 | capitalmarket.com | ||
| 21.03. | Glenmark Gets FDA Approval For Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC) | 441 | AFX News | NEW DELHI (dpa-AFX) - Glenmark Pharmaceuticals Inc., USA announced that it has received final approval from the U.S. Food & Drug Administration (FDA) for its Olopatadine Hydrochloride Ophthalmic... ► Artikel lesen | |
| 21.03. | Stock Alert: Hindustan Unilever, Hindalco Inds, Glenmark Pharma, Ashoka Buildcon | 5 | capitalmarket.com |
1 2 3 4 Weiter >>
69 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SINOPHARM | 2,001 | -0,30 % | Dividendenbekanntmachungen (16.06.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AEGON LTD BMG0112X1056 - 0,19 EUR ALTAGAS LTD CA0213611001 0,315 CAD 0,2007 EUR ALTEN SA FR0000071946 - 1,5 EUR ALTRIA GROUP INC US02209S1033 1... ► Artikel lesen | |
| CSPC PHARMA | 0,890 | +3,90 % | CSPC PHARMA (01093): VOLUNTARY ANNOUNCEMENT - HIGH-CONCENTRATION HYDROXOCOBALAMIN HYDROCHLORIDE INJECTION OBTAINS CLINICAL TRIAL APPROVAL IN CHINA FOR ... | ||
| WUXI BIOLOGICS | 2,752 | -0,88 % | WuXi Biologics-Aktie mit leichten Kursgewinnen (2,762 €) | Im Wertpapierhandel liegt die Aktie von WuXi Biologics derzeit im Plus. Die Aktie notiert zur Stunde bei 2,76 Euro. Am Aktienmarkt liegt die Aktie von WuXi Biologics aktuell im Plus. Das Wertpapier... ► Artikel lesen | |
| SHANGHAI FOSUN PHARMACEUTICAL | 1,782 | -0,11 % | Fosun Pharma prices $34.25M Nature's Sunshine share sale | ||
| GEDEON RICHTER | 25,000 | -0,40 % | Gedeon Richter Plc.: Extraordinary Information | ||
| DR REDDYS | 12,400 | -0,80 % | Dr Reddys Laboratories Ltd slips for fifth straight session | ||
| ASPEN PHARMACARE | 5,700 | -1,72 % | ASPEN PHARMACARE HOLDINGS LIMITED - Notification in Terms of Section 122(3) of the Companies Act and Paragraph 3.83(b) of the JSE Listings Requirements | ||
| SHANGHAI PHARMACEUTICALS | 1,250 | 0,00 % | SH PHARMA (02607): FINAL DIVIDENDS FOR THE YEAR ENDED 31 DECEMBER 2024 (UPDATED) | ||
| LUYE PHARMA | 0,388 | +2,11 % | LUYE PHARMA (02186): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 28 MAY 2025 | ||
| SIHUAN PHARMACEUTICAL HOLDINGS GROUP | 0,118 | -4,84 % | SIHUAN PHARM (00460): VOLUNTARY ANNOUNCEMENT SHARE REPURCHASE | ||
| HANSOH PHARMACEUTICAL | 3,280 | +0,61 % | Dividendenbekanntmachungen (03.07.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABM INDUSTRIES INC US0009571003 0,265 USD 0,2247 EUR AMERICAN EXPRESS COMPANY US0258161092 0,82 USD 0,6955 EUR BIG YELLOW GROUP... ► Artikel lesen | |
| CHINA RESOURCES PHARMACEUTICAL | 0,555 | -1,77 % | Dividendenbekanntmachungen (28.05.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABO ENERGY GMBH & CO KGAA DE0005760029 - 0,65 EUR AIA GROUP LTD HK0000069689 1,3098 HKD 0,1474 EUR ALLIANZ SE ADR US0188201000 1... ► Artikel lesen | |
| CHINA SHINEWAY PHARMACEUTICAL GROUP | 0,880 | +2,33 % | Dividendenbekanntmachungen (30.04.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AG MORTGAGE INVESTMENT TRUST INC US0012285013 0,2 USD EUR ALLIED PROPERTIES REAL ESTATE INVESTMENT ... CA0194561027 0,15 CAD 0... ► Artikel lesen | |
| KALBE FARMA | 0,073 | 0,00 % | KLBF subsidiary partners with GE HealthCare to produce local CT scans: KLBF inaugurates new factory ... | ||
| YICHANG HEC CHANGJIANG PHARMACEUTICAL | - | - | HEC CJ PHARM (01558): SPECIAL DIVIDEND (UPDATED) |
GLENMARK PHARMACEUTICALS LTD gehört der Branche Pharma an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GLENMARK PHARMACEUTICALS LTD finden Sie auf Wallstreet Online.